The owners of Evonik Industries, RAG-Stiftung (74.99%) and CVC Funds (25.01%), together with Evonik's Supervisory Board and Executive Board, confirm that they plan to list the shares of the specialty chemicals company on the stock exchange.

Shares are to be offered to private and institutional investors in Germany and Luxembourg through a public offering. Outside of these countries, the plan is to offer the shares to institutional investors via private placements. In the U.S., the plan is to offer shares to qualified institutional investors under Rule 144A of the U.S. Securities Act of 1933.

The shares are to be listed on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange.

Evonik reported a record performance in 2011, with sales of €14.5 billion and an operating

result (adjusted EBITDA) of €2.8 billion. After adjustment for the carbon black business, which was divested in 2011, Evonik expects that full-year sales in 2012 will be slightly higher than in 2011 and that the operating results will probably be in line with or slightly above the excellent level reported for 2011.

Based on the present timeline, publication of the securities prospectus and the start of trading in the shares is expected to take place before the summer break. Deutsche Bank and Goldman Sachs are Joint Global Coordinators and Joint Bookrunners for the planned IPO.

As additional Joint Bookrunners BofA Merrill Lynch, Credit Suisse and J.P. Morgan are mandated. The IPO advisor for RAG-Stiftung, CVC and Evonik is Lilja & Co.